|Bid||0.8962 x 2200|
|Ask||0.8994 x 900|
|Day's Range||0.8830 - 0.9098|
|52 Week Range||0.7000 - 1.8700|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 10, 2023 - Apr 14, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.13|
TORONTO, January 26, 2023--Organigram Holdings Inc. ("Organigram" or the "Company") (TSX: OGI; NASDAQ: OGI), today announced that it received notification (the "Notification") from The Nasdaq Stock Market LLC ("NASDAQ") that it is not in compliance with the minimum bid price requirement in NASDAQ Listing Rule 5450(a)(1) for continued listing on the NASDAQ Global Select Market, since the closing bid price for the Company’s common shares listed on NASDAQ was below US$1.00 for 30 consecutive tradin
It can be hard for investors to see anything good in the cannabis space through all the smoke of 2022's collapsing share prices. Thanks to the market's general malaise regarding the industry, at least three are selling at discounts and look likely to be great long-term holdings over the next decade: Trulieve Cannabis (OTC: TCNNF), NewLake Capital Partners (OTC: NLCP) and OrganiGram Holdings (NASDAQ: OGI). All three cannabis companies are trading at price-to-book ratios below what their assets would bring if sold off, and at lower ratios than other large cannabis companies such as Canopy Growth and Curaleaf Holdings.
OrganiGram (OGI) delivered earnings and revenue surprises of 0% and 1.43%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?